Nippi Corporation, founded in 1907 and headquartered in Tokyo, is a global leader in collagen-based biomaterials and life science solutions. With a century-long heritage in collagen research—anchored by being the first in the world to patent collagen solubilization—Nippi has since expanded its expertise through the Nippi Research Institute of Biomatrix. This dedicated R&D arm underpins a diverse life science portfolio, including medical- and research-grade collagen, recombinant human laminin substrates for iPS/ES cell culture, and cutting-edge lab tools such as the BioMasher™ series. The BioMasher line comprises disposable tissue homogenizers—available in various formats (I, II, III, V, SP)—designed to efficiently extract DNA, RNA, lipids, and proteins from a wide range of biological samples, and can be paired with the battery-operated PowerMasher II for enhanced processing. Beyond homogenization tools, Nippi supports sophisticated cell culture with offerings like MatriMix and iMatrix laminin fragments, as well as ELISA antigens and antibodies. These products serve biomedical researchers worldwide through applications in regenerative medicine, cell biology, protein analysis, and extracellular matrix engineering. By combining its world-class collagen history with innovation-driven bioscience tools, Nippi continues to uphold its “Quality First” ethos and deliver comprehensive solutions that advance both laboratory research and therapeutic development
